Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline. 

2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

The drug maker presented data from the pivotal Phase II trial at EHA showing median OS of more than two years for Elrexfio.

AstraZeneca’s data showcase its grand strategy in lung cancer, while a trial from Gilead could provide valuable learnings for anti-TROP2 antibodies as they become more competitive - not only on efficacy, but also on safety. J&J and Legend, meanwhile, are nipping at BMS and 2seventy’s heels.